search
  • COMPANY
    • MISSIONS
    • HISTORY
    • MANAGEMENT
    • PARTNERS
  • TECHNOLOGY
    • MEMBRANE PROTEINS
    • EXOSOMES
    • CILOA TECHNOLOGY
    • ADDED VALUE
  • APPLICATION FIELDS
    • ANTIBODIES
    • VACCINES
    • THERAPEUTIC VECTORS
  • WORKING WITH US
  • NEWS
  • CONTACT
    • CAREERS
NEWS

BIO-SOURCING, CILOA AND INTRACT PHARMA LAUNCH €3.4M EU PROJECT IN INFLAMMATORY INDICATIONS WITH €1.9M SUBSIDIES FROM EUREKA EUROSTARS

28 May 2024
AB-BIOBETTER, led by Bio-Sourcing, to pioneer development of new oral formulation of adalimumab for inflammatory bowel diseases; offering patients less…
Read More
Swiss Biotech Days

Ciloa will be presenting its disrupting co-agonist, Adiponectin, that boosts all GLP-1RA therapeutic effects on obesity/diabetes/MASH @Swiss Biotech Days 2024 (Basel, April 22-23)

15 April 2024
Ciloa, a preclinical stage French biotechnology company with a unique exosome bioengineering technology will attend the SwissBiotechDay 2024. Ciloa will be presenting…
Read More

Ciloa speaking @Bio-Europe Spring 2024 (Barcelona, March 18-20)

12 March 2024
Ciloa’s CEO, Robert Z. Mamoun will  be speaking at Bio-Europe Spring 2024. If you’re Interested in therapies for Obesity, Diabetes,…
Read More

Ciloa @Innovative Therapies Days 2023 from 12 to 13 October (Besancon, France)

19 September 2023
Ciloa’s team will  be pleased to be part and sponsor the 3rd Edition of the Innovative Therapy Days ! Come…
Read More

Ciloa @ISEV 2022 from 25 to 29 May (Lyon, France)

12 May 2022
Ciloa’s team will  be pleased to present its last progress on extracellular vesicle (EV) editing and production. Come visit us…
Read More

Ciloa secures €5 million for biomedicines and vaccines development

8 March 2022
Ciloa secures €5 million for the development of its new generation of biomedicines and vaccines using exosomes The company finalized…
Read More
1 2 3 4 … 6 Next
Twitter
LinkedIn
YouTube
RSS

© Ciloa all rights reserved

Legal

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok